RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S.

IBSE:RTALB Stock Report

Market Cap: ₺1.7b

RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret Past Earnings Performance

Past criteria checks 0/6

RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret's earnings have been declining at an average annual rate of -5.7%, while the Biotechs industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 3.5% per year. RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret's return on equity is 1.1%, and it has net margins of 82.6%.

Key information

-5.7%

Earnings growth rate

-8.9%

EPS growth rate

Biotechs Industry Growth14.8%
Revenue growth rate3.5%
Return on equity1.1%
Net Margin82.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

IBSE:RTALB Revenue, expenses and earnings (TRY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24107891919
30 Jun 24106-4143016
31 Mar 241011293314
31 Dec 239603115
30 Sep 231841745917
30 Jun 231812445716
31 Mar 23176-465516
31 Dec 22191-205514
30 Sep 222032233317
30 Jun 222991463918
31 Mar 223681244119
31 Dec 213841144117
30 Sep 21373113409
30 Jun 2130787358
31 Mar 2126776376
31 Dec 2023061315
30 Sep 2012749204
30 Jun 208534134
31 Mar 20341254
31 Dec 1917454
30 Sep 1919766
30 Jun 1919875
31 Mar 1921474
31 Dec 1820274
30 Sep 1824272
30 Jun 1829273
31 Mar 1835373
31 Dec 1738473
30 Sep 1738582
30 Jun 1736382
31 Mar 1733382
31 Dec 1632482
30 Sep 1631482
30 Jun 1633682
31 Mar 1634762
31 Dec 1534772
30 Sep 1531772
30 Jun 1531681
31 Mar 1528571
31 Dec 1426561
30 Sep 1424451
30 Jun 1421531
31 Mar 1420531
31 Dec 1319431

Quality Earnings: RTALB has a high level of non-cash earnings.

Growing Profit Margin: RTALB's current net profit margins (82.6%) are lower than last year (94.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RTALB's earnings have declined by 5.7% per year over the past 5 years.

Accelerating Growth: RTALB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: RTALB had negative earnings growth (-48.9%) over the past year, making it difficult to compare to the Biotechs industry average (5.5%).


Return on Equity

High ROE: RTALB's Return on Equity (1.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies